Profile data is unavailable for this security.
About the company
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
- Revenue in USD (TTM)0.00
- Net income in USD-35.59m
- Incorporated2021
- Employees49.00
- LocationGH Research PLCJoshua Dawson House, Dawson StreetDublin D02 RY95IrelandIRL
- Phone+353 14378334
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 577.69m | 180.00 | -- | 2.19 | -- | 4.64 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Celcuity Inc | 0.00 | -73.45m | 590.76m | 55.00 | -- | 3.87 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Alumis Inc | 0.00 | -168.82m | 593.62m | 107.00 | -- | -- | -- | -- | -3.26 | -3.26 | 0.00 | 2.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -99.34m | 596.81m | 75.00 | -- | 2.52 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Travere Therapeutics Inc | 155.72m | -415.73m | 600.66m | 380.00 | -- | 8.11 | -- | 3.86 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 602.91m | 452.00 | -- | -- | -- | 232.43 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 603.61m | 285.00 | -- | 1.42 | -- | 261.19 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
GH Research PLC | 0.00 | -35.59m | 611.33m | 49.00 | -- | 2.79 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
Mineralys Therapeutics Inc | 0.00 | -90.80m | 617.13m | 28.00 | -- | 1.88 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Scholar Rock Holding Corp | 0.00 | -183.26m | 617.30m | 150.00 | -- | 3.38 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Arrivent Biopharma Inc | -100.00bn | -100.00bn | 622.98m | 40.00 | -- | 1.96 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Humacyte Inc | 0.00 | -105.70m | 627.57m | 183.00 | -- | 24.00 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Zymeworks Inc | 50.46m | -125.97m | 627.86m | 275.00 | -- | 1.44 | -- | 12.44 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Prime Medicine Inc | 591.00k | -204.50m | 628.96m | 234.00 | -- | 2.58 | -- | 1,064.23 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
ProKidney Corp | 0.00 | -35.30m | 637.02m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
SAGE Therapeutics Inc | 91.06m | -503.14m | 648.76m | 487.00 | -- | 0.9192 | -- | 7.12 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 10.40m | 19.99% |
RA Capital Management LPas of 31 Mar 2024 | 6.25m | 12.02% |
RTW Investments LPas of 31 Mar 2024 | 3.33m | 6.40% |
Lynx1 Capital Management LPas of 31 Mar 2024 | 3.31m | 6.36% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.02m | 5.80% |
Verition Fund Management LLCas of 31 Mar 2024 | 1.13m | 2.17% |
Cormorant Asset Management LPas of 31 Mar 2024 | 593.04k | 1.14% |
Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 279.14k | 0.54% |
Checkpoint Capital LPas of 31 Mar 2024 | 185.65k | 0.36% |
Apo Asset Management GmbHas of 30 Sep 2023 | 120.90k | 0.23% |